TY - JOUR
T1 - Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer
AU - Rachagani, Satyanarayana
AU - Macha, Muzafar A
AU - Heimann, Nicholas
AU - Seshacharyulu, Parthasarathy
AU - Haridas, Dhanya
AU - Chugh, Seema
AU - Batra, Surinder K.
N1 - Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Despite considerable progress being made in understanding pancreatic cancer (PC) pathogenesis, it still remains the 10th most often diagnosed malignancy in the world and 4th leading cause of cancer related deaths in the United States with a five year survival rate of only 6%. The aggressive nature, lack of early diagnostic and prognostic markers, late clinical presentation, and limited efficacy of existing treatment regimens make PC a lethal cancer with high mortality and poor prognosis. Therefore, novel reliable biomarkers and molecular targets are urgently needed to combat this deadly disease. MicroRNAs (miRNAs) are short (19-24 nucleotides) non-coding RNA molecules implicated in the regulation of gene expression at post-transcriptional level and play significant roles in various physiological and pathological conditions. Aberrant expression of miRNAs has been reported in several cancers including PC and is implicated in PC pathogenesis and progression, suggesting their utility in diagnosis, prognosis and therapy. In this review, we summarize the role of several miRNAs that regulate various oncogenes (KRAS) and tumor suppressor genes (p53, p16, SMAD4, etc.) involved in PC development, their prospective roles as diagnostic and prognostic markers and as a therapeutic targets.
AB - Despite considerable progress being made in understanding pancreatic cancer (PC) pathogenesis, it still remains the 10th most often diagnosed malignancy in the world and 4th leading cause of cancer related deaths in the United States with a five year survival rate of only 6%. The aggressive nature, lack of early diagnostic and prognostic markers, late clinical presentation, and limited efficacy of existing treatment regimens make PC a lethal cancer with high mortality and poor prognosis. Therefore, novel reliable biomarkers and molecular targets are urgently needed to combat this deadly disease. MicroRNAs (miRNAs) are short (19-24 nucleotides) non-coding RNA molecules implicated in the regulation of gene expression at post-transcriptional level and play significant roles in various physiological and pathological conditions. Aberrant expression of miRNAs has been reported in several cancers including PC and is implicated in PC pathogenesis and progression, suggesting their utility in diagnosis, prognosis and therapy. In this review, we summarize the role of several miRNAs that regulate various oncogenes (KRAS) and tumor suppressor genes (p53, p16, SMAD4, etc.) involved in PC development, their prospective roles as diagnostic and prognostic markers and as a therapeutic targets.
KW - Diagnosis
KW - MiRNA
KW - Pancreatic cancer
KW - Pathogenesis
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=84922254330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922254330&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2014.10.020
DO - 10.1016/j.addr.2014.10.020
M3 - Review article
C2 - 25453266
AN - SCOPUS:84922254330
SN - 0169-409X
VL - 81
SP - 16
EP - 33
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -